Dickter Jana K, Martin Abigail L, Ho Stephanie, Ross Justine A, Shouse Geoffrey P
Division of Infectious Diseases, Department of Medicine, City of Hope National Medical Center, Duarte, CA, USA.
Department of Pharmacy Services, City of Hope National Medical Center, Duarte, CA, USA.
J Clin Pharm Ther. 2021 Aug;46(4):1185-1187. doi: 10.1111/jcpt.13411. Epub 2021 Jun 10.
Treatment for diffuse large B-cell lymphoma (DLBCL) in persons with AIDS consists of chemotherapy alongside antiretroviral therapy (ART). To determine optimal HIV treatment, drug-drug interactions, toxic effects and ART resistance must be considered.
A 40-year-old man with drug-resistant HIV and DLBCL initiating chemotherapy which had drug interactions with his ART. During chemotherapy, darunavir/cobicistat was held and ibalizumab-uiyk was started to ensure he was on three active HIV medications.
Ibalizumab-uiyk has no known drug-drug interactions and may be used as bridge therapy for patients with drug-resistant HIV undergoing chemotherapy.
艾滋病患者弥漫性大B细胞淋巴瘤（DLBCL）的治疗包括化疗及抗逆转录病毒疗法（ART）。为确定最佳的HIV治疗方案，必须考虑药物相互作用、毒性作用及ART耐药性。
一名40岁的耐药HIV及DLBCL男性患者开始化疗，化疗药物与他正在使用的ART存在药物相互作用。化疗期间，停用了达芦那韦/考比司他，并开始使用依巴珠单抗-乌伊克，以确保他服用三种有效的HIV药物。
依巴珠单抗-乌伊克不存在已知的药物相互作用，可作为正在接受化疗的耐药HIV患者的桥接治疗药物。
